Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Labetuzumab after colon cancer resection to prevent liver metastases
ACTRN12623001333606Phase 2Not yet recruiting
- Sponsor
- St George Hospital
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in colon adenocarcinoma and colon cancer comparing High-risk labetuzumab, High-risk placebo and Low-risk observation (3 arms). Primary endpoint: Development of metachronous liver metastases related to primary colon cancer in high-risk randomized patients. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
labetuzumab
03
Conditions
colon adenocarcinomacolon cancer
Beyond the preview
Go deeper on ACTRN12623001333606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001333606.